In addition to a busy clinical practice, I have a research lab focused on thyroid cancer with two ongoing research projects. The first is examining a novel AMPK activator for the treatment of thyroid cancer. I’m currently studying the mechanism of action to potentially use synergistically with known BRAF inhibitors. My second research project is creating a molecular imaging agent for medullary thyroid cancer (MTC) and parathyroid tumors. The calcium sensing-receptor (CaSR) is expressed primarily on parathyroids, thyroid C-cells and the kidney, as well as in MTC. Further development may allow pre-operative and intra-operative detection to improve surgical outcomes.
Here at Ohio State we’re fortunate to have one of the few – and best – multidisciplinary treatment teams in the country. We care for patients while also focusing on cutting-edge research. Our team at the OSUCCC – James is a part of two large, multi-investigator NIH grants of more than $25 million dollars funding thyroid cancer research. The camaraderie and expertise among my colleagues is fantastic. There is a singular focus among us, and that’s to create a cancer-free world.
University of California San Francisco Medical Center
General Surgery/Surgical Oncology
Washington University Hospital
7/1/1994 - 6/30/2002
Specialties and conditions I treat
- Surgical Oncology
- Parathyroid Diseases
- Adrenal Gland Cancers
- Carcinoma, Neuroendocrine
- Adrenocortical Adenoma
- Adrenocortical Carcinoma
- Thyroid Cancer
- Parathyroid Cancers
- Gastrointestinal Cancers
- Minimally Invasive Surgical Procedures
Locations where I practice
More about my work
American Board of Surgery
News about me
Consulting and Related Relationships
At The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the University requires annual disclosures from all faculty members with external interests related to their University responsibilities.
As of 03/28/17, Dr. Phay has reported no financial relationships with medical device, research and/or drug companies.